Literature DB >> 23397210

Diffuse panbronchiolitis after humanized anti-CCR4 monoclonal antibody therapy for relapsed adult T-cell leukemia/lymphoma.

Koji Kato1, Toshihiro Miyamoto, Akihiko Numata, Takashi Nakaike, Hideyo Oka, Ayano Yurino, Takuro Kuriyama, Yasuo Mori, Satoshi Yamasaki, Tsuyoshi Muta, Katsuto Takenaka, Hiromi Iwasaki, Takanori Teshima, Koichi Akashi.   

Abstract

We present the case of a 62-year-old Japanese woman with relapsed adult T-cell leukemia/lymphoma (ATLL) who was treated with humanized anti-CCR4 monoclonal antibody (KW-0761). Although this antibody was highly effective against refractory ATLL, 6 months after the final KW-0761 infusion, the patient complained of hypoxia due to diffuse panbronchiolitis. Physicians should remain vigilant to the possibility of such previously unreported late-onset adverse effects associated with KW-0761 therapy.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23397210     DOI： 10.1007/s12185-013-1278-z

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  16 in total

1.  Uveitis associated with human T lymphotropic virus type I: seroepidemiologic, clinical, and virologic studies.

Authors:  M Mochizuki; T Watanabe; K Yamaguchi; K Tajima; K Yoshimura; S Nakashima; M Shirao; S Araki; N Miyata; S Mori
Journal:  J Infect Dis       Date:  1992-10       Impact factor: 5.226

2.  Diffuse panbronchiolitis as a pulmonary complication in patients with adult T-cell leukemia.

Authors:  K Ono; Y Shimamoto; M Matsuzaki; M Sano; T Yamaguchi; O Kato; H Yamada; M Yamaguchi
Journal:  Am J Hematol       Date:  1989-02       Impact factor: 10.047

Review 3.  Diffuse panbronchiolitis.

Authors:  V Poletti; G Casoni; M Chilosi; M Zompatori
Journal:  Eur Respir J       Date:  2006-10       Impact factor: 16.671

4.  HTLV-I associated myelopathy, a new clinical entity.

Authors:  M Osame; K Usuku; S Izumo; N Ijichi; H Amitani; A Igata; M Matsumoto; M Tara
Journal:  Lancet       Date:  1986-05-03       Impact factor: 79.321

5.  Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.

Authors:  Kazuhito Yamamoto; Atae Utsunomiya; Kensei Tobinai; Kunihiro Tsukasaki; Naokuni Uike; Kimiharu Uozumi; Kazunari Yamaguchi; Yasuaki Yamada; Shuichi Hanada; Kazuo Tamura; Shigeo Nakamura; Hiroshi Inagaki; Koichi Ohshima; Hitoshi Kiyoi; Takashi Ishida; Kouji Matsushima; Shiro Akinaga; Michinori Ogura; Masao Tomonaga; Ryuzo Ueda
Journal:  J Clin Oncol       Date:  2010-02-22       Impact factor: 44.544

6.  High concentrations of beta-chemokines in BAL fluid of patients with diffuse panbronchiolitis.

Authors:  J Kadota; H Mukae; K Tomono; S Kohno
Journal:  Chest       Date:  2001-08       Impact factor: 9.410

7.  Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege.

Authors:  Takashi Ishida; Toshihiko Ishii; Atsushi Inagaki; Hiroki Yano; Hirokazu Komatsu; Shinsuke Iida; Hiroshi Inagaki; Ryuzo Ueda
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

8.  Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease.

Authors:  S Jacobson; H Shida; D E McFarlin; A S Fauci; S Koenig
Journal:  Nature       Date:  1990-11-15       Impact factor: 49.962

Review 9.  Chronic bronchioloalveolitis associated with human T-cell lymphotrophic virus type I infection.

Authors:  M Sugimoto; M Kitaichi; A Ikeda; S Nagai; T Izumi
Journal:  Curr Opin Pulm Med       Date:  1998-03       Impact factor: 3.155

10.  CT scans of the chest in carriers of human T-cell lymphotropic virus type 1: presence of interstitial pneumonia.

Authors:  Tsuneo Yamashiro; Hisashi Kamiya; Tetsuhiro Miyara; Shinji Gibo; Kazuhiko Ogawa; Tamaki Akamine; Hidekazu Moromizato; Satomi Yara; Sadayuki Murayama
Journal:  Acad Radiol       Date:  2012-05-10       Impact factor: 3.173
View more
  6 in total

Review 1.  Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.

Authors:  Catherine J Hutchings; Markus Koglin; William C Olson; Fiona H Marshall
Journal:  Nat Rev Drug Discov       Date:  2017-07-14       Impact factor: 84.694

2.  Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab.

Authors:  Kenji Ishitsuka; Mutsunori Murahashi; Hiroo Katsuya; Ai Mogi; Michio Masaki; Chisato Kawai; Toshitaka Goto; Masanao Ishizu; Yosuke Ikari; Yasushi Takamatsu; Hideki Ishibashi; Satoshi Nimura; Morishige Takeshita; Kazuo Tamura
Journal:  Int J Hematol       Date:  2015-05-21       Impact factor: 2.490

Review 3.  Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.

Authors:  Regan Stephenson; Ankur Singh
Journal:  Adv Drug Deliv Rev       Date:  2017-06-15       Impact factor: 15.470

Review 4.  Targets, Toxins, and T Cells--a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas.

Authors:  Jonathan Hebb; Holbrook Kohrt
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 4.213

Review 5.  Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges.

Authors:  Maria Vela; Mariana Aris; Mercedes Llorente; Jose A Garcia-Sanz; Leonor Kremer
Journal:  Front Immunol       Date:  2015-01-30       Impact factor: 7.561

Review 6.  Recent Advances in Therapeutic Approaches for Adult T-cell Leukemia/Lymphoma.

Authors:  Koji Kato; Koichi Akashi
Journal:  Viruses       Date:  2015-12-14       Impact factor: 5.048
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.